At my neuro appointment today, he brought up Ocrevus as I knew he would. He has ordered blood tests as the first step towards switching me from Tysabri. I'm in the high PML risk category so he has been wanting to switch me off of Tysabri for some time. If I 'pass' the blood tests, then we go to the next step.
I asked him about PML risk since Ocrevus hasn't been available all that long. He agreed with me that it's an unknown at this point. He further said since it's similar in mechanism to Rituxan, it will likely be a similar risk which is far lower than the risk with Tysabri.
I read through the Ocrevus for RRMS guide he gave me. It mentions both the PML risk and the cancer risk. As to the PML risk it says although no cases have been seen, that it could happen. DUH! It talks about the cancer risk under possible side effects which I thought was an odd way to describe it. It goes on to say you should follow your Healthcare provider's instructions about standard screening guidelines. Again...DUH . I guess you can't expect a lot of detail in what are basically marketing materials.
Since the protocols for administration and the enrollment process aren't firmed up from what my neuro told me, it's unlikely I will be switched until late summer at the soonist. It still makes me feel like a lab rat.